Active	Status	Sponsor type	Region	Phase	Filter
4 Active 4 Inactive 8 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

4 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
HERBRECHT, Raoul
OASIS, NCT05101187: Olorofim Aspergillus Infection Study	Recruiting	3	225	Europe, Canada, Japan, US, RoW	Olorofim, Olorofim (F901318), AmBisome®, AmBisome® (liposomal amphotericin B)	F2G Biotech GmbH, Iqvia Pty Ltd, Shionogi	Invasive Aspergillosis	09/25	11/26
FORMULA-OLS, NCT03583164 / 2017-001290-17: Evaluate F901318 (Olorofim) Treatment of Invasive Fungal Infections in Participants Lacking Treatment Options	Completed	2	203	Europe, US, RoW	Olorofim, F901318	F2G Biotech GmbH, Iqvia Pty Ltd	Invasive Fungal Infections	02/23	02/23
NHYP, NCT03156595: Demonstrate the Value of Using Hypnosis in Chimiotherapy- Induced Chronic Neuropathies	Recruiting	N/A	108	Europe	Nurse interview, Listening time, Hypnosis sessions	University Hospital, Strasbourg, France	Chemotherapy-induced Neuropathy	11/21	11/21
MAURER, Caroline
NHYP, NCT03156595: Demonstrate the Value of Using Hypnosis in Chimiotherapy- Induced Chronic Neuropathies	Recruiting	N/A	108	Europe	Nurse interview, Listening time, Hypnosis sessions	University Hospital, Strasbourg, France	Chemotherapy-induced Neuropathy	11/21	11/21